 |
|
|
|
|
FDA Starts Safety Review of Autoimmune Disorder Drugs
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 | 3 "TNF plays an important role in immune surveillance and, by blocking it, you might be interfering with the body's own defenses," Putterman said.
The FDA has requested that makers of TNF blockers approved for use in children and young adults supply information about all reported cases of cancer in children and young adults taking the drugs.
The maker of Cimzia, UCB Inc., must conduct a study looking at the long-term risks of this drug. That study will begin in 2009, and will take about a decade to complete.
Text Continues Below
In the meantime, the FDA has asked health-care professionals to weigh the possible risks against the benefits when prescribing TNF blockers.
More information
Read about TNF blockers U.S. Food and Drug Administration.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 6/4/2008
|
|
SOURCES: Chaim Putterman, M.D., chief, division of rheumatology, Montefiore Medical Center and Albert Einstein College of Medicine, New York City; Stephen Lindsey, head, rheumatology, Ochsner Health Service, Baton Rouge, La.; June 4, 2008, U.S. Food and Drug Administration statement
|
.gif)
